Cardiac stem cell therapy promises to be a new phase in the treatment of coronary artery and heart disease. In a number of clinical trials, adult stem cells have been shown to reverse the damage in the heart caused by lack of blood flow. This provides a new option to patients who have already reached the peak benefit from medication, surgery and stents. It can also be a treatment for people who have heart damage, and who wish to have a minimally invasive approach to help the heart repair itself.
Cardiac cell therapy is the delivery of adult stem cells to the heart to repair tissue that is diseased or has been damaged by a heart attack. Clinical trials have shown strong indications of efficacy, resulting in improvement of symptoms and quality of life.
Okyanos Heart Institute is the leading provider of cardiac cell therapy to treat chronic coronary artery disease. The procedure is minimally invasive, requires only a local anesthetic and takes approximately four hours.
Based on the PRECISE clinical trial, cell therapy has shown important improvements in quality of life including reduced major adverse cardiac events, reduced re-hospitalizations, and reduced angina.
The Okyanos cell therapy procedure is performed on candidates who have been full medically-screened, and who have had interventions such as by-pass or stents and who have heart damage.
The PRECISE clinical trial was designed to examine the safety and feasability of cell therapy treatment in those with severe heart disease. The findings suggest that heart function can be improved using cells from the patient’s own body.